8.5.1 ABSTRACT: IMMUNOLOGY The Immunology program, lead by Yoji Shimizu, Ph.D., has 16 members, representing seven departments and three schools. As of September 30,2007, these members have a total of $8.1 million in peer-reviewed, funded research projects for the current budget period. Since June 2003, their research has resulted in 163 publications, of which 15% were intra-programmatic and 28% were inter-programmatic. The scientific goals of the program are to elucidate the basic mechanisms that underlie the development and function of the immune system, and to use this information to enhance the evaluation, development and implementation of effective anti-cancer immunotherapies. Research activities in the program are focused on four research themes: mechanisms, of lymphocyte tolerance, lymphocyte activation and signal transduction, lymphocyte development, and tumor immunology/immunotherapy. Significant strength in cellular and molecular immunology has allowed Immunology program investigators to develop novel technical approaches for the analysis and quantitation of the immune response in vivo that have led to seminal insights into the development and function of the adaptive immune response. Intra-programmatic collaborations are facilitated by regular group meetings, common research space for program investigators, and a NIH-funded program project on peripheral tolerance. Intra-programmatic and inter-programmatic collaborations, coupled with new faculty recruitment, have enhanced translational research activities within the program. These activities have allowed program investigators to utilize basic research insights obtained within the program as a foundation for the development and testing of specific immunotherapeutic approaches designed to enhance the immune response to cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-15
Application #
8449988
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
15
Fiscal Year
2013
Total Cost
$70,280
Indirect Cost
$23,738
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Sarver, Aaron L; Murray, Collin D; Temiz, Nuri A et al. (2016) MYC and PVT1 synergize to regulate RSPO1 levels in breast cancer. Cell Cycle 15:881-5
Diep, Caroline H; Knutson, Todd P; Lange, Carol A (2016) Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming. Mol Cancer Res 14:141-62
Yun, Young Sung; Kim, Kwan Hyun; Tschida, Barbara et al. (2016) mTORC1 Coordinates Protein Synthesis and Immunoproteasome Formation via PRAS40 to Prevent Accumulation of Protein Stress. Mol Cell 61:625-39
Yan, Y; Hanse, E A; Stedman, K et al. (2016) Transcription factor C/EBP-β induces tumor-suppressor phosphatase PHLPP2 through repression of the miR-17-92 cluster in differentiating AML cells. Cell Death Differ 23:1232-42
Beura, Lalit K; Hamilton, Sara E; Bi, Kevin et al. (2016) Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 532:512-6
Than, B L N; Linnekamp, J F; Starr, T K et al. (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 35:4179-87
Struntz, Nicholas B; Harki, Daniel A (2016) Catch and Release DNA Decoys: Capture and Photochemical Dissociation of NF-κB Transcription Factors. ACS Chem Biol 11:1631-8
Knorr, David A; Wang, Hongbo; Aurora, Mukta et al. (2016) Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 22:825-33
Glasgow, Michelle; Vogel, Rachel Isaksson; Burgart, Jennifer et al. (2016) Long term follow-up of a phase II trial of multimodal therapy given in a ""sandwich"" method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol Res Pract 3:6
Felices, Martin; Lenvik, Todd R; Davis, Zachary B et al. (2016) Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells. Methods Mol Biol 1441:333-46

Showing the most recent 10 out of 763 publications